Pathways from diagnosis to death from keratinocyte cancer in kidney transplant recipients
Name:
35439759.pdf
Size:
221.8Kb
Format:
PDF
Description:
Identified with Open Access button
Affiliation
QIMR Berghofer Medical Research Institute, Herston, Queensland, AustraliaIssue Date
2022
Metadata
Show full item recordAbstract
Background: Kidney transplant recipients are at increased risk of developing and dying from keratinocyte cancer. We aimed to describe the clinical course of keratinocyte cancer-related deaths in a cohort of kidney transplant recipients. Methods: In kidney transplant recipients transplanted between 1995 and 2014 in Queensland, Australia, we ascertained keratinocyte cancer deaths by searching national transplant and state death registries to March 2020. Deceased transplant recipients' medical records were reviewed to assess features of the primary lesion of the fatal keratinocyte cancer, metastases, and clinical information before death. Results: Of 658 kidney transplant recipient deaths, 49 (7%) were due to keratinocyte cancer, and medical records were available for 36 (73%). One death was due to basal cell carcinoma, and 35 were from squamous cell carcinoma (SCC), primarily from the head and neck (24; 69%). The most common site of metastasis was the lungs (21; 58%). Median time (minimum, maximum) from the diagnosis of primary SCC to metastasis was 5 months (0, 29). After this, the median time to death was 9 months (1, 50). Conclusion: Fatal keratinocyte cancers overwhelmingly arise on the head and neck, with lungs the most common metastasis site. The short time from diagnosis of primary to death indicates the aggressive nature of these keratinocyte cancers.Citation
Shao EX, Khosrotehrani K, Campbell S, Isbel N, Green A. Pathways from Diagnosis to Death from Keratinocyte Cancer in Kidney Transplant Recipients. Dermatology. S. Karger AG; 2022. p. 1–8.Journal
DermatologyDOI
10.1159/000524120PubMed ID
35439759Additional Links
https://dx.doi.org/10.1159/000524120Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1159/000524120
Scopus Count
Collections
Related articles
- Keratinocyte Cancer Mortality in Kidney Transplant Recipients.
- Authors: Shao EX, Betz-Stablein B, Khosrotehrani K, Campbell S, Isbel N, Green AC
- Issue date: 2022 May 1
- Association between Use of Hydrochlorothiazide and Risk of Keratinocyte Cancers in Kidney Transplant Recipients.
- Authors: Letellier T, Le Borgne F, Kerleau C, Gaultier A, Dantal J, Ville S, Divat Consortium
- Issue date: 2020 Dec 7
- Risk of Second Malignancies in Solid Organ Transplant Recipients Who Develop Keratinocyte Cancers.
- Authors: Zamoiski RD, Yanik E, Gibson TM, Cahoon EK, Madeleine MM, Lynch CF, Gustafson S, Goodman MT, Skeans M, Israni AK, Engels EA, Morton LM
- Issue date: 2017 Aug 1
- Higher mycophenolate dosage is associated with an increased risk of squamous cell carcinoma in kidney transplant recipients.
- Authors: Shao EX, Betz-Stablein B, Marquat L, Campbell S, Isbel N, Green AC, Plasmeijer EI
- Issue date: 2022 Dec
- The presence of betapapillomavirus antibodies around transplantation predicts the development of keratinocyte carcinoma in organ transplant recipients: a cohort study.
- Authors: Genders RE, Mazlom H, Michel A, Plasmeijer EI, Quint KD, Pawlita M, van der Meijden E, Waterboer T, de Fijter H, Claas FH, Wolterbeek R, Feltkamp MCW, Bouwes Bavinck JN
- Issue date: 2015 May